---
raindrop_id: 730083723
raindrop_highlights:
  65c0fbcf9b19504e3e9b942e: 9ae088c83ca9da5c732920106a7e1b0f
  65c0fbe7697d2fd7e33f25ce: ef434f5f3430654d814388abdc81be1b
  65c0fbfb98b28552b10f3e25: c9b124026497cc20b7f0dc7dc5f74460
  65c0fc1d697d2fd7e33f3515: e3e471f9b1d8f6c3567f4c47293518f5
  65c0fc266e9bf4a893710de4: a62e79fbfb067cbdb9c2c38e4037fb51
  65c0fc3649b2c62881302098: dc6341cbf609dbf374375aa256e12768
  65c0fc3d697d2fd7e33f3d9f: 99484bd6d2f027155aec8f0c0eed20e6
  65c0fc4549b2c628813025a0: 222cffd3458aecc2982969f7f0e77468
  65c0fc5a9cfb4459a65a8049: 35d67d57def1275d4f4fb113e2bcd9cf
  65c0fc6b75c9cec0e9683dd4: 11294760295c3a6ce14f0708e9397f62
  65c0fc72697d2fd7e33f4d3a: feb76ee028e5a773be9fd56e1ca9e17a
  65c0fc7b697d2fd7e33f4f08: bcf840fa3528cd7001bff4640e5c7570
  65c0fc7e697d2fd7e33f4f96: 8efb21058f0483783b89eec71ac44470
  65c0fc85644cde30734e8c2d: e533c83f241cb64470c84ea8582e07ff
  65c0fed993dca37808a338ff: 5dc248a1470f7eb4145efcdcc200805c
  65c0ff58644cde30734f1147: 72b5849826e5179220f7eeb2138c5596
  65c0ff6698b28552b10fea5e: 1aeb594d6d0a9fca9bd2424371e2d094
  65c0ff8a9cfb4459a65b1c12: fb22ee1c1a63d492f99169eafd3f20f5
  65c0ff9093dca37808a358da: ad7e6ea1dc68cd97e2a1ed2c54ec2fa9
  65c0ffa7644cde30734f1ee8: 5b8fab5b08692bc81ebc126b8b19d43a
  65c0ffe293dca37808a367b6: 7c272e2a59eb7532feff7be423f31cad
  65c0ffeb6e9bf4a89371c904: e287127f5d908f99e1bcacdc48e8dcb4
  65c0fff66e9bf4a89371cad6: 242d479af50e2f0142d07400f875ea7b
  65c100029cfb4459a65b3074: 86ca33ec9ac7180f393f5e49c7c1d957
  65c10015644cde30734f31cf: b6f1293fe0f85a7fbf329ac002dd3d48
---

# Metadata
Source URL:: https://link.springer.com/article/10.1007/s44192-022-00030-1/tables/1


---
# An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder

Discover Mental Health - Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent psychiatric condition characterized by developmentally inappropriate symptoms of inattention and/or...

## Highlights

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> D1, D2, D3, D4, and D5 dopaminergic receptors

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Higher density of the dopamine transporter (DAT) [92] and altered D2/D3 receptor availability—responsive to methylphenidate

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Drugs used for ADHD treatment (e.g., methylphenidate, amphetamines [104, 105], and bupropion [106]), inhibit the reuptake of dopamine

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> ADHD is associated with decreased noradrenaline transporter (NET) availability in fronto-parietal-thalamic-cerebellar regions [103]

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Poor performance in sustained attention tasks correlated with lower levels of urinary excretion of noradrenaline metabolites in ADHD patients

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Methylphenidate, amphetamines [104, 105], and atomoxetine [109] inhibit NET, while α-receptors are targeted by guanfacine and clonidine [110

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Regulation of cognitive functions (e.g. working memory), arousal, and alertness

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Noradrenergic

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Dopaminergic

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Mediation of cognitive, motor, attentional, emotional, and reward processes

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> adrenergic receptors

> [!info]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Serotonergic

> [!info]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> 5HT receptors

> [!info]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Involvement in sleep, appetite, mood, and emotional regulation

> [!info]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Low serotonin levels in fasting venous blood are associated with ADHD

> [!info]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Cerebrospinal fluid levels of serotonin positively correlated with symptoms of hyperactivity

> [!danger]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Glutamatergic

> [!danger]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> Ionotropic (NMDA, AMPA and kainate) and metabotropic (mGluR1-mGluR8) glutamate receptors

> [!danger]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> learning and memory)

> [!danger]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> increased glutamate levels in the anterior cingulate cortex are associated with ADHD (enhanced excitability

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> glutamatergic tone in the frontal and striatal brain

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> GABAergic

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> motor control and behavioral inhibition

> [!check]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> reduced GABA levels in the anterior cingulate, somatosensory, and motor cortices in ADHD (impaired response inhibition) [97

> [!quote]+ Updated on Mon Feb 05 2024 23:34:45 GMT+0800
>
> NMDA N -methyl-D-aspartate, AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid, GABA gamma-aminobutyric acid, 5HT serotonin
